Clinical trial
An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis
NCT02525874 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis
- Lead sponsor
- Biogen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 11, 2015
- Completion date
- April 23, 2018
- Enrollment
- 218 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.